Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Eoganachton Nov 21, 2023 12:25pm
347 Views
Post# 35746666

RE:RE:RE:More good news, maybe

RE:RE:RE:More good news, maybeHi enrique - six months ago, as of 30 May 2023, 39 patients had hit 450 days (15 months) 9 days from now, all of those 39 patients should have reached 21 months after their first treatment and 18 months after their initial CR.
 
33% (13 patients) of these 39 patients were CR at 450 days
5% (2 patients) of these 39 patients were IR at 450 days
38% (15) were responders

If there is an MD&A on Wednesday November 29, this would be a very opportune time to let us know how these CRs have held up at 18 months past their initial CR.

enriquesuave wrote: Nice analysis Eoganacht! If they want to see 18 months post initial CR, then that would be patients who are 21 months in after initial treatment.  Anyone know how many patients hit 21 months post initial treatment?


<< Previous
Bullboard Posts
Next >>